tachments. The tube had to be occluded using a 6-0 Vicryl suture (Ethicon, Inc, Piscataway, NJ) 3 mm posteriortothelimbus.Subsequentexaminationundergeneralanesthesiarevealed a dense retroprosthetic membrane with no view of the fundus. B-scanultrasonographyrevealedatotal choroidal and retinal detachment. The patient underwent revision of a pars planavitrectomywithmembranepeeling, scleral buckle, fluid-air exchange, endolaser photocoagulation, and silicone oil tamponade. Two months following the retinal detachment repair, anavascularretroprostheticmembrane was noted. This thin membrane was successfully treated with Nd:YAG capsulotomy without complications. The keratoprosthesis remained in place 15 months after the surgery, allowing for a clear view of the fundus. The eye remained soft to palpation, with an intraocular pressure of less than 10 mm Hg as measured by the Tono-Pen. The patient currently wears a contact lens of ϩ26 diopters (D) for refractive purposes. The patient's vision is hand motions.
Nopostoperativecomplicationsoccurred in patient 2. The most recent examination under general anesthesia 14 months following placement of the keratoprosthesis revealed a wellpositioned keratoprosthesis and tube shunt in the right eye with a clear view of the fundus. The sectoral iridectomy temporally in the left eye allowed for a clear view of the fundus. The intraocular pressures remained in the high teensandlow20sinbotheyes.Theoptic cups were large but improved to a cup-disc ratio of 0.7, and the rims were intact. The patient wears a contact lens of −4 D OD and is able to fixate and follow with each eye.
Comment.
Although congenital corneal opacities in the pediatric population are infrequent, they pose a great challenge for cornea specialists owing to the difficulties in surgical management. Poor prognostic categories in the PK pediatric group include young age (particularly Ͻ1 year) at the time of transplantation, children with anterior segment dysgeneses such as Peters' anomaly, associated comorbidity such as glaucoma, and regrafting.
Keratoprosthesis implantation has the goal of replacing the central cornea with a clear optical cylinder made of an immunologically inert material. Therefore, allograft rejection does not occur with the keratoprosthesis. Another significant advantage is that the keratoprosthesis maintains a spherical anterior shape. Furthermore, the Boston type I keratoprosthesis, a polymethyl methacrylate device, can be custom made such that it can correct for refractive errors as well as aphakia. These advantages are particularly important in cases of pediatric PK. Immunologic graft rejection in children can be insidious and often eludes parents' detection. Maintaining a clear visual axis while minimizing the induced astigmatism in the immediate postoperative period may minimize the development of amblyopia in this age group. The goal in cases of significant bilateral congenital corneal opacity is to minimize the amount of time that a child is not seeing clearly until he or she nears the end of the amblyopic age range. Theoretically, keratoprosthesis implantation may provide faster and superior visual results as compared with conventional donor corneal transplantation. The device can possibly be removed and replaced by a PK when the child is out of the amblyopic age range.
Corneal blindness remains the leading cause of pediatric blindness globally. 5, 6 In particular, infectious keratitis is the most common cause of corneal scarring in developing countries. Importantly, in the majority of these cases, the occurrence of corneal opacification is associated with poverty in areas devoid of eyebanking and transplantation-quality corneas. Regrettably, no significant developments in pediatric corneal transplantation have been achieved in recent years, and the results of pediatric PK remain poor even in developed countries. Although the postoperative complications may be severe enough to limit the use of currently available devices, we believe that the keratoprosthesis might have a role in the management of corneal blindness in carefully selected children with complex ocular diseases who are at high risk for graft failure. Intravascular large B-cell lymphoma is a rare form of extranodal lymphoma characterized by the presence of large lymphoma cells in the lumen of small blood vessels, involving multiple organs. The diagnosis is usually made at the time of autopsy. We report a patient with intravascular large B-cell lymphoma who had vision loss from choroidal involvement, which improved with systemic therapy. blurred vision, Coombs-negative hemolytic anemia, and a maculopapular skin rash on both upper arms. The patient's best-corrected visual acuity (Snellen) was OD 20/40 −2 and OS 20/50. There were bilateral serous detachments involving the macula ( Figure 1A) . A small, superficial intraretinal hemorrhage was noted along the inferotemporal vascular arcade in the right eye, and peripheral flame-shaped intraretinal hemorrhages were present in both eyes. Fluorescein and indocyanine green angiography demonstrated irregular filling of the choroid early with bilateral pinpoint areas of fluorescence later (1 day) ( Figure 1C) . B-scan ultrasonography showed thickening of the choroid bilaterally ( Figure 1B) .
The patient had a normocytic anemia with an increased reticulocyte count, lactate dehydrogenase level, and bilirubin concentration. A computed tomographic scan of his chest and abdomen showed hazy groundglass infiltrates throughout the lungs (Figure 2A) , splenomegaly, and diffuse edema within the subcutaneous tissues of the thorax and abdomen. A biopsy specimen of his skin lesions showed nonspecific inflammatory cell infiltration of the dermis. A bone marrow biopsy specimen revealed hypercellularity with trilineage hyperplasia consistent with a peripheral destructive process. The blood smear demonstrated several atypical lymphocytes with convoluted nuclei. Cerebrospinal fluid examination re sults were normal, while a lung biopsy specimen revealed large, atypical CD20-positive and CD3-negative lymphocytes filling the lumen of the capillaries in the alveolar septae ( Figure 2B and C) . These findings were diagnostic of malignant intravascular lymphoma of B-cell phenotype (intravascular lymphomatosis).
Aregimenofhyper-CVAD(cycle 1: cyclophosphamide, vincristine, doxorubicin, and dexamethasone) chemotherapy, intrathecal methotrexate and cytarabine, and methylprednisolone was initiated 10 days after initial examination. A week later, there was a marked improvement in visual acuity (20/20 OU) and resolution of serous detachments and choroidal thickening, shown by repeat fluorescein angiography and indocyanine green angiography ( Figure 1E and F) . The patient continued to do well 2 months after starting therapy.
Comment. Intravascular large Bcell lymphoma is a rare form of extranodal malignant lymphoma in which the lymphoid cells are principally found within small vessels without extensive involvement of bone marrow or lymphoid tissue. 1 Aberrant expression or deletion of certain cell adhesion molecules critical for lymphocyte trafficking and transvascular migration (CD29 and CD54) contributes to the tumor's intravascular and disseminated pattern of distribution. 2 The tumor expresses CD20 and other B-cell markers and does not express the T-cell marker CD3. 3 At diagnosis, the lymphoma typically involves various organs, including the central nervous system, skin, lung, kidneys, spleen, and adrenal glands. 4 Other types of lymphoma may separately coexist with intravascular large B-cell lymphoma in the same patient. 2 Hematologic abnormalities, like microangiopathic and autoimmune hemolytic anemia, as in our case, are often associated with this disease process. 1 The prognosis is generally very poor because of the usually delayed diagnosis. Intravascular large B-cell lymphoma can also involve the small vessels of the choroid. The case presented herein adds the eye as another end organ involved by this rare malignancy.
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